| |

Adjuvant Radiotherapy Most Effective for Pleural Mesothelioma in Early Stages

ByAlex Strauss
adjuvant radiotherapy for esothelioma

New research shows adjuvant radiotherapy is most likely to help pleural mesothelioma patients in the early stages of the disease. By the time mesothelioma is at Stage III or Stage IV, adjuvant radiotherapy is unlikely to improve survival.

Researchers at MD Anderson Cancer Center in Texas conducted the study on more than 2,500 pleural mesothelioma patients. Their results appear in the most recent issue of the Journal of Thoracic Disease.

The study could help mesothelioma patients and doctors make more informed choices about their care.

Defining the Stages of Pleural Mesothelioma

The four stages of mesothelioma relate to the severity of the cancer and how far it has spread.

In Stage I mesothelioma, the tumor is confined to the pleural membrane and has not spread. Stage I mesothelioma is the most responsive to treatments like surgery, adjuvant radiotherapy, and chemotherapy. Patients with Stage I mesothelioma have the longest life expectancy.

Mesothelioma patients with Stage II disease may have some mesothelioma in nearby organs but no mesothelioma cells in their lymph nodes.

In Stage III and IV, tumors are larger and have spread to other organs and lymph nodes. At this stage, treatment options are more limited and survival is often much shorter.

Doctors use the staging system to help determine mesothelioma prognosis. Knowing the patient’s stage can help them decide whether or not to perform surgery or offer additional treatments like adjuvant radiotherapy.

Adjuvant Radiotherapy and Mesothelioma Survival

The new study uses information from the National Cancer Database. Doctors reviewed the cases of 2,846 pleural mesothelioma patients. The patients all had mesothelioma surgery between 2004 and 2013.

Two hundred and thirteen of the patients (7%) had adjuvant radiotherapy after surgery. Adjuvant therapy is treatment delivered after the primary treatment is complete.  

The researchers compared the outcomes of the patients who had surgery and radiation with the stage of their cancer when they started.

“Adjuvant radiation was associated with improved survival among those who were stage I-II (P=0.024), but not stage III or IV,” writes study author David B. Nelson. Patients in the later stages of mesothelioma lived for about the same amount of time as those who did not have any adjuvant radiotherapy.

The shortest survival times were in people with Stage IV sarcomatoid mesothelioma.

The research team is calling for more study on the usefulness of adjuvant radiotherapy in people with pleural mesothelioma.

Source:

Nelson, DB, et al, “Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database”, April 2019, Journal of Thoracic Disease, pp. 1269-1278, http://jtd.amegroups.com/article/view/28310/20869

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

Value of Mesothelioma Surgery Challenged for Healthy Patients
| |

Value of Mesothelioma Surgery Challenged for Healthy Patients

ByAlex Strauss

New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…